Tying U.S. Drug Prices To Foreign Markets Risks Innovation And Lives

What’s next for Trump’s ‘most favored nation’ policy?

HHS set drug price targets last week for pharma manufacturers, while lawmakers proposed new reforms.

Tying U.S. Drug Prices To Foreign Markets Risks Innovation And Lives

Pegging drug prices here to those in other countries would yield minimal savings for the United States and devastate funding for biomedical research.

Last week President Trump issued an executive order to offer prices of "most-favoured-nation" (MFN) drugs to American patients. The order’s goal is to equalize the imbalance in drug prices between the United States and the rest of the world and for the United States to pay the lowest price, but the exact mechanism by which Trump intends to achieve it remains unclear. Verbal pressure on big pharmaceuticals could be enough to induce change.

Game-Changer for Drug Prices: HHS Steps in to End Outrageous Costs

WASHINGTON, D.C. — The U.S. Department of Health and Human Services (HHS) has announced plans to enforce President Donald J. Trump’s Executive Order on Most-Favored-Nation (MFN) Prescription Drug Pricing. This initiative, unveiled on May 20, 2025, is designed to lower healthcare costs by aligning U.S. drug prices with those paid in economically comparable countries. The order mandates pharmaceutical manufacturers to match U.S. drug prices for br…